|
Name |
4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
|
Molecular Formula | C15H23NO4 | |
IUPAC Name* |
4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
|
|
SMILES |
C[C@H]1C[C@@H](C(=O)[C@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C
|
|
InChI |
InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11+,12+/m0/s1
|
|
InChIKey |
YPHMISFOHDHNIV-GAIPPQHRSA-N
|
|
Synonyms |
Naramycin B; 642-81-9; 4-[(2R)-2-[(1R,3S,5S)-3,5-Dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-piperidinedione; NCGC00024910-01; Tocris-0970; 4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione; CHEMBL1078564; CHEBI:95322; DTXSID30859063; TNP00309; NCGC00017363-01; NCGC00017363-02; Q27167192
|
|
CAS | 642-81-9 | |
PubChem CID | 120760 | |
ChEMBL ID | CHEMBL1078564 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 281.35 | ALogp: | 0.5 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.768 |
Caco-2 Permeability: | -4.805 | MDCK Permeability: | 0.00003510 |
Pgp-inhibitor: | 0.013 | Pgp-substrate: | 0.128 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.991 | Plasma Protein Binding (PPB): | 25.16% |
Volume Distribution (VD): | 0.548 | Fu: | 67.77% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.237 |
CYP2C19-inhibitor: | 0.066 | CYP2C19-substrate: | 0.768 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.515 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.114 |
CYP3A4-inhibitor: | 0.04 | CYP3A4-substrate: | 0.203 |
Clearance (CL): | 10.625 | Half-life (T1/2): | 0.896 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.726 |
Drug-inuced Liver Injury (DILI): | 0.663 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.979 | Maximum Recommended Daily Dose: | 0.138 |
Skin Sensitization: | 0.238 | Carcinogencity: | 0.297 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.071 |
Respiratory Toxicity: | 0.041 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001890 | 1.000 | D07XVN | 0.247 | ||||
ENC005741 | 0.536 | D0WB9V | 0.219 | ||||
ENC005740 | 0.536 | D03QWT | 0.212 | ||||
ENC001024 | 0.333 | D0I5DS | 0.210 | ||||
ENC005846 | 0.244 | D0R2KF | 0.207 | ||||
ENC005972 | 0.244 | D0O5FY | 0.206 | ||||
ENC003132 | 0.242 | D00ETS | 0.205 | ||||
ENC002048 | 0.240 | D06WTZ | 0.196 | ||||
ENC004873 | 0.237 | D0S8LV | 0.196 | ||||
ENC004874 | 0.237 | D03WAJ | 0.195 |